Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
Latest Information Update: 26 Nov 2024
At a glance
- Drugs Carboplatin (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
Most Recent Events
- 22 Nov 2024 Status changed from active, no longer recruiting to completed.
- 14 Feb 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 14 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2025.